News

University of Southampton acknowledges Pelago Bioscience’s patent and use of CETSA® process

Pelago Bioscience is excited about University of Southampton researchers, led by Professor Tavassoli, having found our patented CETSA® technology useful in their research into identifying hypoxia-inducible factor (HIF) inhibitors. The research inProfessor Tavassoli’s group has led to the identification of cyclic peptide that inhibits bothHIF-1 and HIF-2, as described in patent application WO2022106825A1, with cellular target engagement for the lead molecule confirmed using Pelago’s CETSA® technology.

Our mission at Pelago Bioscience is make sure all drug discovery projects know their targets before entering into clinical trials. Therefore, we encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA® technology and services can bring to enhance their drug discovery efforts.

Stockholm, 22 November 2024